SEC ownership of Neurogene Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001404644.

Comparable stake leader

RTW INVESTMENTS, LP

Disclosed value leader

Redmile Group, LLC

Comparable rows

50/50

Latest evidence

30 Jun 2026

Top shareholders Insider holders Latest transactions

Public ticker: NGNE on Nasdaq
Parsed ownership sources: 13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder: RTW INVESTMENTS, LP
Ranking: Comparable ownership first, then disclosed value
Comparable ownership rows: 50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder: RTW INVESTMENTS, LP
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date: 30 Jun 2026
Freshness: Most recent filing date in this holder set
Issuer CIK: 0001404644
Issuer location: New York, NY

Ownership snapshot

Top shareholders of Neurogene Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

RTW INVESTMENTS, LP

Disclosed value leader

Redmile Group, LLC

Comparable rows

50/50

Latest evidence

30 Jun 2026

13F 13D/G 3/4/5 Lead comparable stake: 10% 13D/G row: RTW INVESTMENTS, LP Showing 1-8 of 50 holder rows.

Quick read

RTW INVESTMENTS, LP leads the comparable SEC ownership view at 10%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RTW INVESTMENTS, LP's linked filing trail.

Comparable ownership Top 5

RTW INVESTMENTS, LP 10%

Redmile Group, LLC 9.9%

EcoR1 Capital, LLC 9.9%

Casdin Capital, LLC 8.7%

BAKER BROS. ADVISORS LP 7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
RTW INVESTMENTS, LP	13F 13D/G Company 13F 13D/G	10% from 13D/G	$42,849,241 1,362,456 shares	—	30 Jun 2026
Redmile Group, LLC	13D/G 13F Company 13D/G 13F	9.9%	$60,121,004 1,572,202 shares	+$574,480	30 Jun 2026
EcoR1 Capital, LLC	13F 13D/G Company 13F 13D/G	9.9% from 13D/G	$39,983,706 1,271,342 shares	—	30 Jun 2026
Casdin Capital, LLC	13F 13D/G Company 13F 13D/G	8.7% from 13D/G	$48,601,603 1,545,361 shares	—	30 Jun 2026
BAKER BROS. ADVISORS LP	13F 13D/G 3/4/5 Company · Julian C. Baker · Director, Former 10% Owner 13F 13D/G 3/4/5	7% from 13D/G	$31,188,682 991,691 shares	—	30 Jun 2026
BlackRock, Inc.	13F 13D/G Company 13F 13D/G	6.8% from 13D/G	$33,273,565 1,057,983 shares	—	30 Jun 2026
BALYASNY ASSET MANAGEMENT L.P.	13D/G 13F Company 13D/G 13F	5.2%	$31,307,317 818,706 shares	$0	30 Jun 2026
Trails Edge Capital Partners, LP	13D/G 13F Company 13D/G 13F	4.5%	$27,337,202 714,885 shares	-$2,681,198	30 Jun 2026

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$1,133,592.

Buys

Insiders: 0

Sells

$1,133,592

Insiders: 4

Net

-$1,133,592

Shares: -41,580

Window

Last 12 months

4 rolling buckets

Buy value Sell value

Shares: 0 Shares: 41,580

Window (months)	Sell shares	Buy value	Sell value	Net value
0-3	9,600	$0	$339,962	-$339,962
3-6	27,180	$0	$673,104	-$673,104
6-9	4,800	$0	$120,526	-$120,526
9-12	0	$0	$0	$0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 25 reporting-owner rows connected to Neurogene Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows

Largest Forms 3/4/5 holder

Samsara BioCapital GP, LLC

Net 12M change

-$1,133,592

Latest report

06 Jul 2026

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Samsara BioCapital GP, LLC	10%+ Owner	$47,220,993			Filing P/S	26 Nov 2024
Rachel McMinn	Chief Executive Officer, Director	$29,675,442	-$73,995	-0.25%	Filing P/S	26 Mar 2026
Christine Mikail Cvijic	President and CFO, Director	$3,036,701	-$900,023	-23%	Filing P/S	06 Jul 2026
Stuart Cobb	Chief Scientific Officer	$673,373	-$141,446	-17%	Filing P/S	13 Mar 2026
BAKER BROS. ADVISORS LP	Director, Former 10% Owner	$287,276			Mixed	18 Dec 2023
Julie Jordan	Chief Medical Officer	$273,051	-$18,128	-6.2%	Filing P/S	26 Mar 2026
Priti Patel	Former Chief Medical Officer	$25,850			Mixed	31 Mar 2023
Sean Michael Smith	Interim CFO, Prin Acct Off	$14,990			Mixed	10 Aug 2023
Jonathan G. Drachman	President and CEO, Director				Mixed	02 Aug 2022
Robert Ho	Chief Financial Officer				Mixed	01 Feb 2022
Holly Vance	General Counsel				Mixed	03 Aug 2021
Donna Cochener	General Counsel, SVP Legal				Mixed	02 Aug 2022
Erin Lavelle	Director				Mixed	08 Jun 2023
Martin Babler	Director				Mixed	08 Jun 2023
Todd E. Simpson	Director				Mixed	08 Jun 2023
Erin M. Lavelle	Director				Mixed	11 May 2021
Carl Walkey	Senior Vice President				Mixed	02 Aug 2022
Lewis T. "rusty" Williams	Director				Mixed	11 May 2021
Robert Baffi	Director				Mixed	20 Feb 2026
Rohan Palekar	Director				Mixed	20 Feb 2026

Recent insider transactions for Neurogene Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	SEC-reported value	SEC-reported price	Shares	Shares owned	Date	Ownership
Christine Mikail Cvijic	NGNE	Common Stock	Sale	-4.76%	$151,763	$36.13	-4,200	84,040	07 Jul 2026	Direct
Christine Mikail Cvijic	NGNE	Common Stock	Sale	-0.68%	$21,613	$36.02	-600	88,240	06 Jul 2026	Direct
Christine Mikail Cvijic	NGNE	Common Stock	Sale	-4.37%	$141,417	$34.82	-4,061	88,840	02 Jul 2026	Direct
Christine Mikail Cvijic	NGNE	Common Stock	Sale	-0.79%	$25,170	$34.06	-739	92,901	01 Jul 2026	Direct
Christine Mikail Cvijic	NGNE	Common Stock	Sale	-9.3%	$300,043	$31.25	-9,600	93,640	06 May 2026	Direct
Christina Shafer	NGNE	Non-Qualified Stock Option (right to buy)	Award				120,000	120,000	05 May 2026	Direct
Christine Mikail Cvijic	NGNE	Common Stock	Sale	-2.42%	$55,316	$21.62	-2,558	103,240	26 Mar 2026	Direct
Rachel McMinn	NGNE	Common Stock	Sale	-0.25%	$73,995	$22.07	-3,352	1,344,307	26 Mar 2026	Direct
Julie Jordan	NGNE	Common Stock	Sale	-6.23%	$18,128	$21.89	-828	12,472	26 Mar 2026	Direct
Stuart Cobb	NGNE	Common Stock	Sale	-18.2%	$141,446	$20.81	-6,797	30,497	13 Mar 2026	Direct
Christine Mikail Cvijic	NGNE	Common Stock	Sale	-3.68%	$84,176	$20.81	-4,045	105,798	13 Mar 2026	Direct
Christine Mikail Cvijic	NGNE	Common Stock	Sale	-4.19%	$120,526	$25.11	-4,800	109,843	27 Feb 2026	Direct
Stuart Cobb	NGNE	Common Stock	Award	79.4%			16,500	37,294	20 Feb 2026	Direct
Julie Jordan	NGNE	Common Stock	Award	58.3%			4,900	13,300	20 Feb 2026	Direct
Julie Jordan	NGNE	Stock Option (Right to Buy)	Award				29,600	29,600	20 Feb 2026	Direct
Christine Mikail Cvijic	NGNE	Common Stock	Award	23.8%			22,000	114,643	20 Feb 2026	Direct
Christine Mikail Cvijic	NGNE	Stock Option (Right to Buy)	Award				131,900	131,900	20 Feb 2026	Direct
Rachel McMinn	NGNE	Common Stock	Award	1.96%			25,900	1,347,659	20 Feb 2026	Direct
Rachel McMinn	NGNE	Stock Option (Right to Buy)	Award				155,100	155,100	20 Feb 2026	Direct
Rohan Palekar	NGNE	Non-Qualified Stock Option (right to buy)	Award				12,050	12,050	20 Feb 2026	Direct
Robert Baffi	NGNE	Non-Qualified Stock Option (right to buy)	Award				12,050	12,050	20 Feb 2026	Direct
Sarah B. Noonberg	NGNE	Non-Qualified Stock Option (right to buy)	Award				12,050	12,050	20 Feb 2026	Direct
Cory S. Freedland	NGNE	Non-Qualified Stock Option (right to buy)	Award				12,050	12,050	20 Feb 2026	Direct
Keith Woods	NGNE	Non-Qualified Stock Option (right to buy)	Award				12,050	12,050	20 Feb 2026	Direct

^* marks a reported price that did not pass the local price check.